SCHEMBL8596242

SCHEMBL8596242

NC(=O)NCC1CCC(C(=O)O)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.76
PLG P00747 1/20 0.55
PLAT P00750 1/20 0.55
LMNA P02545 1/20 0.55
KMT2A Q03164 3/20 0.46
ANPEP P15144 1/20 0.44
ENPEP Q07075 1/20 0.44
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.42
CYP2C9 P11712 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2D6 P10635 1/20 0.42
EPHX1 P07099 1/20 0.41
VCP P55072 6/20 0.40
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8596237 1.00 TDP1 (0.76) TDP1PLGPLATLMNAKMT2A
SCHEMBL2000699 0.87
SCHEMBL483345 0.85 TDP1 (0.53) TDP1PLGPLATLMNAKMT2A
SCHEMBL483347 0.85 TDP1 (0.53) TDP1PLGPLATLMNAKMT2A
Hydrochloric Acid SCHEMBL11285176 0.83 TDP1 (0.52) TDP1PLGPLATLMNAKMT2A
Hydrochloric Acid SCHEMBL11285151 0.83 TDP1 (0.52) TDP1PLGPLATLMNAKMT2A
Hydrochloric Acid SCHEMBL7443981 0.83 TDP1 (0.52) TDP1PLGPLATLMNAKMT2A
Hydrochloric Acid SCHEMBL5505595 0.83 TDP1 (0.52) TDP1PLGPLATLMNAKMT2A
Hydrochloric Acid SCHEMBL10894938 0.82 TDP1 (0.50) TDP1PLGPLATLMNAKMT2A
SCHEMBL8601731 0.81 PLG (0.57) TDP1PLGPLATLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
US-10292955-B2 Composition for external use preparation with improved transdermal permeability HYUNDAI PHARM CO., LTD. (KR) 2019-05-21 US disclosed
US-20160058723-A1 COMPOSITION FOR EXTERNAL USE PREPARATION WITH IMPROVED TRANSDERMAL PERMEABILITY HYUNDAI PHARM CO., LTD. (KR) 2016-03-03 US disclosed
EP-0585130-B1 External preparation for skin containing a depigmentation agent SHISEIDO CO LTD (JP) 1998-01-28 EP disclosed
US-5690914-A TRANEXAMIC ACID DERIVATIVES FOR DEPIGMENTATION SHISEIDO CO., LTD (JP) 1997-11-25 US disclosed
EP-0585130-A2 External preparation for skin containing a depigmentation agent SHISEIDO COMPANY LIMITED (JP) 1994-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT TDP1 1933/4885PLG 917/4885PLAT 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.